Last reviewed · How we verify
Joint pain — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aleve | naproxen | Generic (originally Syntex) | NSAID | Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1 | 1976-01-01 | |
| Acetaminophen | Paracetamol | Polymedica | acetaminophen | Transient receptor potential cation channel subfamily V member 4 | 1968-01-01 | |
| Norgesic | acetylsalicylic acid | Endo | centrally acting muscle relaxant with anticholinergic properties | reticular formation (brain stem) | 1950-01-01 | |
| Norgesic | caffeine | Hikma | Central Nervous System Stimulant [EPC] | Adenosine receptor A2a | 1948-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Joint pain
- Endo · 1 drug in Joint pain
- Generic (originally Syntex) · 1 drug in Joint pain
- Hikma · 1 drug in Joint pain
- Polymedica · 1 drug in Joint pain
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Joint pain:
- Joint pain treatment updates — RSS
- Joint pain treatment updates — Atom
- Joint pain treatment updates — JSON
Cite this brief
Drug Landscape (2026). Joint pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/joint-pain. Accessed 2026-06-10.
Related
- Joint pain full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing